Tetracycline, Vancomycin, Linezolid Flashcards
Vancomycin Chemistry
(Vancosin)
Complex tricyclic glycopeptide
Vancomycin Spectrum of Action
Bacteriocidal VS Most Gram+ cocci and bacilli and blocks cell wall synthesis; IV Vancomycin used to treat sepsis or endocarditis caused by MRSA, Oral Vancomycin used to treat colitis caused by C. difficile - Poorly absorbed so remains GI tract; Oral Vancomycin used when Metronidazole (Flagyl) use is contraindicated in presence of liver disease or alcoholism or when 2 14-day courses of Metronidazole are ineffective; Oral Vancomycin is first drug choice for recurrent of severe C.difficile infection with AAC
Vancomycin Mechanism of Action
Bacteriocidal, Inhibits cell wall synthesis by binding very tightly to acyl-D-alanyl-D-alanine terminus of cell wall precursor unit to inhibit peptidoglycan polymerization leading to cell lysis
Vancomycin Pharmacokinetics
Administered IV for systemic action or oral for GI action, Well distributed including CSF inflammation, Excreted in urine as unchanged or does not concentrate in bile, 55% bound to proteins
Vancomycin Resistance
Resistance to Vancomycin occurs when bacterium acquire DNA encoding enzymes that make D-Ala-D-Lactate that does not bind Vancomycin well - 2 enzymes are responsible - Van H is dehydrogenase that makes D-Lactate from pyruvate and Van A is ligase that links D-Ala to D-Lactate
Vancomycin Adverse Effects
Rapid IV causes red-neck or red-man syndrome (flushing, tachycardia, hypotension and rash over neck, face, chest, wheezing, difficulty breathing), Due to Histamine release - Give IV slowly to avoid or pre injection antihistamines; Ototoxic - Permanent hearing loss possible, Nephrotoxic Less with current preparations
Vancomycin Dosing
Vancomycin HCl pulses/Oral Vancomycin - First line therapy for initial or recurrent of severe CDI - Rx Vancomycin 125mg capsule, q6h 10-14days, Ineffective for systemic infections; Second recurrence treated with Oral Vancomycin tapered over 4wks - Pulse dosing prescription 1capsule q2-3days for 2-8wks; Systemic Infection - Rx Vancomycin 7.5mg/kg BW or 500mg-1g IV - 6-12hrs
Teicoplanin
Similar to Vancomycin, IM or IV, Nephrotoxicity and Ototoxicity rare
Linezolid
(Zyvox) Oxazolidinones; Active VS Gram+ organisms, Mycobacterium TB, Used for VRSA, Belong to oxazolidinones class of antibiotics, Inhibit protein synthesis by binding to 23S ribosomal RNA of 50S subunit and prevent formation of ribosome complex that initiates protein synthesis; Other agents- Prosizolid, Tedizolid
Linezolid Pharmacokinetics
Taken oral with full bioavailability, T1/2 = 4-6hrs, No effect on P450 enzyme system, Dose is 600mg twice daily, Oral
Linezolid Uses
Used to treat Vancomycin resistant E. faecium infections, pneumonia, and skin and soft tissue infection - Off-label use to treat multi-drug resistant TB and Nocardia infections
Linezolid Adverse Effects
Short Term - Nausea, Vomiting, Diarrhea, Headache, Rash
Long Term - Bone marrow suppression, thrombocytopenia, constipation, dizziness, peripheral neuropathy, optic neuropathy, lactic acidosis are late onset side effects; Teeth and tongue discolor
Weak MAOI action - Cause Serotonin syndrome with SSRI, meperidine etc avoid tyramine rich foods
Linezolid Drug Intercations
Monitor concurrent admin of sympathomimetic agents and Linezolid - Increase BP
Mechanism of synergistic sympathomimetic effect due to enhanced NE storage in adrenergic neurons (MAOI activity) and increased liberation of catecholamines (Indirect sympathomimetic activity)
Quinupristin-Dalfopristin Mechanism of Action
Streptogramins; Combine Quinupristin (Strept-B) and Dalfopristin (Strept-A) in 30:70 ratio - Synergistic - A binds to 23S (of 50S) and changes conformation so B is 100X enhanced - A Inhibits peptidyl transferase - B binds 50S and prevents elongation of polypeptide (Clindamycin and Macrolides)
Bacteriocidal against many organism - Gram + cocci including MDR Strep, penicillin resistant S. pneumonia MRSA and Enterococcus faecium (not cidal) - Used to treat bone and joint infections = Bacteremias - E.faecalis is intrinsically resistant
Quinupristin-Dalfopristin
Streptogramins; Administer IV, Eliminate fecal, Both inhibit CYP3A4 which metabolizes warfarin, cyclosporin, NNRTI, resistance due to ribosomal modification, enzyme inactivation of Dalfopristin or efflux, Arthralgias and myalgias were most common adverse events related to treatment